High expression of PRDX1 has been correlated with an unfavorable prognosis in AML patients, indicating that targeting of PRDX1 by CCW16 might be a therapeutic option in a subset of AML patients (Hassan et al, 2024). The gene discussed is PRDX1; the disease is acute myeloid leukemia.